KRAS, NRAS, and BRAF mutation profiling for solid tumor research. Offered by Genient Technologies as part of its expanded Oncology NGS portfolio.
A fastGEN solid tumor NGS kit for laboratories evaluating KRAS, NRAS, and BRAF mutation status from tumor-derived or circulating DNA.
A quick view of the product fit, marker scope, and workflow notes for laboratory planning.
RUO. Availability and intended use can vary by market; contact Genient for current guidance.
KRAS, NRAS, BRAF
Isolated DNA sequencing workflow support.
GENOVESA cloud workflow support for FASTQ analysis and reporting discussions.
Our team can help with assay selection, availability, implementation planning, and sequencing workflow fit.
